Biologics, such as TNF-α inhibitors, IL-12/IL-23 inhibitors, IL-17 inhibitors, and IL-23/IL-39 inhibitors are now considered first-line therapy in moderate to severe psoriasis [2]. This evidence concerns the gene IL17A and psoriasis.